CN110520442A - 多特异性抗体、抗体偶联物和相关的药物组合物及应用 - Google Patents

多特异性抗体、抗体偶联物和相关的药物组合物及应用 Download PDF

Info

Publication number
CN110520442A
CN110520442A CN201880018652.4A CN201880018652A CN110520442A CN 110520442 A CN110520442 A CN 110520442A CN 201880018652 A CN201880018652 A CN 201880018652A CN 110520442 A CN110520442 A CN 110520442A
Authority
CN
China
Prior art keywords
her2
antibody
fab
cells
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880018652.4A
Other languages
English (en)
Inventor
王�忠
于浩洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Benhealth Biopharmaceutic Shenzhen Co ltd
Original Assignee
Benhealth Biopharmaceutic Shenzhen Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benhealth Biopharmaceutic Shenzhen Co ltd filed Critical Benhealth Biopharmaceutic Shenzhen Co ltd
Publication of CN110520442A publication Critical patent/CN110520442A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供了靶向HER2胞外结构域II和免疫效应细胞上的抗原的多特异性抗体以及所述抗体与纳米粒子的偶联物，所述偶联物可以进一步包含特异性结合HER2胞外结构域IV的结合部分。还提供了包含所述多特异性抗体或其偶联物的药物组合物，以及所述多特异性抗体或其偶联物在制备用于治疗HER2阳性肿瘤的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880018652.4A 2017-03-17 2018-03-16 多特异性抗体、抗体偶联物和相关的药物组合物及应用 Pending CN110520442A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710159566 2017-03-17
CN2017101595662 2017-03-17
PCT/CN2018/079284 WO2018166527A1 (zh) 2017-03-17 2018-03-16 多特异性抗体、抗体偶联物和相关的药物组合物及应用

Publications (1)

Publication Number Publication Date
CN110520442A true CN110520442A (zh) 2019-11-29

Family

ID=63521756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880018652.4A Pending CN110520442A (zh) 2017-03-17 2018-03-16 多特异性抗体、抗体偶联物和相关的药物组合物及应用

Country Status (2)

Country Link
CN (1) CN110520442A (zh)
WO (1) WO2018166527A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4291167A1 (en) * 2021-05-07 2023-12-20 University of Notre Dame du Lac Bispecific nanoparticle systems for targeting cancer cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104829728A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体her2xcd3的构建及应用
CN105829347A (zh) * 2013-12-20 2016-08-03 豪夫迈·罗氏有限公司 双特异性her2抗体及使用方法
WO2016165632A1 (zh) * 2015-04-14 2016-10-20 深圳市中联生物科技开发有限公司 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
CN106188305A (zh) * 2015-06-01 2016-12-07 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195992A (zh) * 2016-04-29 2019-01-11 本康生物制药（深圳）有限公司 多特异性结合偶联物、相关的药物组合物及应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829347A (zh) * 2013-12-20 2016-08-03 豪夫迈·罗氏有限公司 双特异性her2抗体及使用方法
CN104829728A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体her2xcd3的构建及应用
WO2016165632A1 (zh) * 2015-04-14 2016-10-20 深圳市中联生物科技开发有限公司 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
CN106188305A (zh) * 2015-06-01 2016-12-07 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AIFEN LI等: "A single‑domain antibody‑linked Fab bispecific antibody Her2‑S‑Fab has potent cytotoxicity against Her2‑expressing tumor cells", 《AMB EXPR》 *
GHISLAINE BEHAR等: "Isolation and characterization of anti-FcgRIII (CD16) llama single-domain antibodies that activate natural killer cells", 《PROTEIN ENGINEERING, DESIGN & SELECTION》 *
LILLIAN S. SHAHIED等: "Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Also Published As

Publication number Publication date
WO2018166527A1 (zh) 2018-09-20

Similar Documents

Publication Publication Date Title
JP6906653B2 (ja) 三重特異性結合タンパク質と使用方法
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
CA2953992C (en) Bispecific cd33 and cd3 binding proteins
AU2018297061B2 (en) Antibodies that modulate a biological activity expressed by a cell
TW201927824A (zh) 三鏈抗體、其製備方法及其用途
TW201946655A (zh) 新型抗體分子、其製備方法及其用途
AU2018297058B2 (en) Bispecific anti PD1-anti TIM3 antibodies
JP2021524278A (ja) 抗メソテリン抗体
EP3502142B1 (en) Bispecific antibody and antibody conjugate for tumour therapy and use thereof
WO2016192613A1 (zh) 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
CN111699201A (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
JP7365654B2 (ja) 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体
JP2023504733A (ja) 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片
KR102399028B1 (ko) 이중-특이적 항원-결합 폴리펩티드
CN110520442A (zh) 多特异性抗体、抗体偶联物和相关的药物组合物及应用
CN111655733A (zh) 共价多特异性抗体
KR20230042524A (ko) 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
JP2023530720A (ja) Ｌｅｗｉｓ Ｙに対するヒト化抗体
JP2021508468A (ja) メディトープ対応ｔ細胞
CN114773485B (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
TW202340240A (zh) 多特異性抗體及其藥物用途
JP2024508672A (ja) 新規抗ｃｄ２４抗体
CN117964767A (zh) 抗rage抗体、细胞外囊泡及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination